Lung cancer immunotherapy is to regulate the body’s immune function by using biology and chemistry to achieve the effect of treating the disease, and the commonly used drugs are nabumab, pembrolizumab and so on. Lung cancer is a kind of malignant tumor disease originated from bronchial mucosa or glands in the lung. Immunotherapy of lung cancer is the focus of clinical research at present, which uses biology, chemistry or physics to regulate the immune function of the body, activate the immune system and kill the cancer cells, so as to achieve the purpose of treating the disease. Clinical immune drugs for the treatment of lung cancer include nabumab, pembrolizumab, pabolizumab monotherapy and so on. Usually, for lung cancer, immunotherapy is mainly the first-line treatment for advanced non-small cell lung cancer. It is recommended that patients should choose appropriate treatment methods and drugs under the guidance of doctors, actively cooperate with doctors in treatment and follow up on time.